Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01983462 · ClinicalTrials.gov registry record · Phase 2
Vascular Dysfunction in Human Obesity Hypertension
A Phase 2 study, sponsored by Gary L. Pierce.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT01983462 is a Phase 2 study that was terminated before completion, run by Gary L. Pierce. The registered enrollment target is 33 participants.
The verdict
NCT01983462, a Phase 2 study, was terminated before completion, sponsored by Gary L. Pierce.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of the study is to test the effects of blocking sympathetic nerve activity with a drug called clonidine on blood vessel function and muscle nerve activity in adults who are obese and have high blood pressure. The cohort of subjects will consist of 69 healthy young men and women age 18-79 years who are obese, defined as a body mass index \> or = to 30 kg/m2, who have untreated systolic hypertension (systolic blood pressure \> or = to 130 - \<180 mmHg- average of at least 3 measurements 2 min apart after 10 min seated resting position). These 69 subjects will then be randomized to 3 treatment arms: clonidine (0.1 mg/day), hydrochlorothiazide (25 mg/day) or placebo for 4 weeks in years 1 and 2. All tablets will be encapsulated by to look identical. Subjects will randomly (1:1:1) receive one of the following combinations in a double-blind, placebo-controlled design: 1. Oral clonidine (0.1 mg twice/day) 2. Oral hydrochlorothiazide (12.5 mg twice/day) 3. Oral placebo I
Interventions
- DRUG Placebo
- DRUG Clonidine
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-10 |
| Est. Completion | 2020-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01983462
The ClinicalTrials.gov registry entry for NCT01983462 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gary L. Pierce, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01983462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01983462 about?
NCT01983462 is a clinical study titled "Vascular Dysfunction in Human Obesity Hypertension". The purpose of the study is to test the effects of blocking sympathetic nerve activity with a drug called clonidine on blood vessel function and muscle nerve activity in adults who are obese and have high blood pressure. The cohort of subjects will consist of 69 healthy young men and women age 18-7...
What is the current status of trial NCT01983462?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2013-10. Estimated completion is 2020-06.
What interventions are being tested in trial NCT01983462?
The interventions under investigation include: Placebo (DRUG), Clonidine (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT01983462?
This trial is sponsored by Gary L. Pierce, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.